First Time Loading...

Nektar Therapeutics
NASDAQ:NKTR

Watchlist Manager
Nektar Therapeutics Logo
Nektar Therapeutics
NASDAQ:NKTR
Watchlist
Price: 0.9342 USD 5.55% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

NKTR's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. [ Read More ]

The intrinsic value of one NKTR stock under the Base Case scenario is 1.9074 USD. Compared to the current market price of 0.9342 USD, Nektar Therapeutics is Undervalued by 51%.

Key Points:
NKTR Intrinsic Value
Base Case
1.9074 USD
Undervaluation 51%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Nektar Therapeutics

Backtest NKTR Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling NKTR stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of Nektar Therapeutics's business.

What risks and challenges
does Nektar Therapeutics face in the near future?

Summarize the latest earnings report
of Nektar Therapeutics.

Provide P/E
for Nektar Therapeutics and its competitors.

Financials

Balance Sheet Decomposition
Nektar Therapeutics

Current Assets 330.7m
Cash & Short-Term Investments 303.6m
Receivables 1.2m
Other Current Assets 25.9m
Non-Current Assets 67.3m
Long-Term Investments 25.8m
PP&E 36.9m
Other Non-Current Assets 4.6m
Current Liabilities 51.3m
Accounts Payable 9.8m
Accrued Liabilities 41.4m
Non-Current Liabilities 215.8m
Other Non-Current Liabilities 215.8m
Efficiency

Earnings Waterfall
Nektar Therapeutics

Revenue
90.1m USD
Cost of Revenue
-33.8m USD
Gross Profit
56.4m USD
Operating Expenses
-191.6m USD
Operating Income
-135.2m USD
Other Expenses
-140.8m USD
Net Income
-276.1m USD

Free Cash Flow Analysis
Nektar Therapeutics

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

NKTR Profitability Score
Profitability Due Diligence

Nektar Therapeutics's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Negative 1-Year Revenue Growth
Negative Revenue Growth Forecast
Declining ROE
16/100
Profitability
Score

Nektar Therapeutics's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

NKTR Solvency Score
Solvency Due Diligence

Nektar Therapeutics's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
55/100
Solvency
Score

Nektar Therapeutics's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NKTR Price Targets Summary
Nektar Therapeutics

Wall Street analysts forecast NKTR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NKTR is 1.02 USD with a low forecast of 1.01 USD and a high forecast of 1.05 USD.

Lowest
Price Target
1.01 USD
8% Upside
Average
Price Target
1.02 USD
9% Upside
Highest
Price Target
1.05 USD
12% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

NKTR Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

NKTR Price
Nektar Therapeutics

1M 1M
+32%
6M 6M
+56%
1Y 1Y
+28%
3Y 3Y
-95%
5Y 5Y
-97%
10Y 10Y
-92%
Annual Price Range
0.9342
52w Low
0.42
52w High
1.05
Price Metrics
Average Annual Return -40%
Standard Deviation of Annual Returns 30.71%
Max Drawdown -99%
Shares Statistics
Market Capitalization 178.8m USD
Shares Outstanding 183 618 000
Percentage of Shares Shorted 2.34%

NKTR Return Decomposition
Main factors of price return

What is price return decomposition?

NKTR News

Last Important Events
Nektar Therapeutics

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Nektar Therapeutics

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Nektar Therapeutics Logo
Nektar Therapeutics

Country

United States of America

Industry

Pharmaceuticals

Market Cap

178.8m USD

Dividend Yield

0%

Description

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.

Contact

CALIFORNIA
San Francisco
455 Mission Bay Blvd S
+14154825300.0
http://www.nektar.com/

IPO

1994-05-03

Employees

740

Officers

CEO, President & Director
Mr. Howard W. Robin
Senior VP, Chief Legal Officer & Secretary
Mr. Mark A. Wilson
Senior VP & Chief Research and Development Officer
Dr. Jonathan Zalevsky Ph.D.
Chief Financial Officer
Ms. Sandra A. Gardiner
Director of Investor Relations & Corporate Affairs
Vivian Wu
Senior Vice President of Human Resources & Facilities Operations
Mr. Robert Bacci
Show More
Chief Business Officer
Ms. Jennifer Ruddock
Chief Medical Officer
Dr. Mary Tagliaferri L.Ac., M.D.
VP and Head of Discovery & Research
Dr. Loui T. Madakamutil
Show Less

See Also

Discover More
What is the Intrinsic Value of one NKTR stock?

The intrinsic value of one NKTR stock under the Base Case scenario is 1.9074 USD.

Is NKTR stock undervalued or overvalued?

Compared to the current market price of 0.9342 USD, Nektar Therapeutics is Undervalued by 51%.